Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ASND NASDAQ:IONS NASDAQ:RARE NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.10-1.0%$21.69$19.69▼$28.35$3.61B0.861.75 million shs1.38 million shsASNDAscendis Pharma A/S$247.05-0.2%$232.68$153.49▼$250.74$15.41B0.41739,020 shs450,896 shsIONSIonis Pharmaceuticals$75.56-0.3%$74.18$32.00▼$86.74$12.49B0.381.93 million shs1.58 million shsRAREUltragenyx Pharmaceutical$23.39-1.3%$23.22$18.29▼$42.37$2.30B0.391.72 million shs1.13 million shsUTHRUnited Therapeutics$568.43+0.5%$563.25$272.12▼$609.35$24.13B0.6415,129 shs281,045 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%-1.40%-4.57%-12.05%-3.43%ASNDAscendis Pharma A/S0.00%+2.72%+9.80%+9.80%+56.26%IONSIonis Pharmaceuticals0.00%+1.79%+1.98%-9.13%+125.55%RAREUltragenyx Pharmaceutical0.00%-6.44%-3.67%+2.95%-33.95%UTHRUnited Therapeutics0.00%-0.03%-0.77%+20.07%+83.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.10-1.0%$21.69$19.69▼$28.35$3.61B0.861.75 million shs1.38 million shsASNDAscendis Pharma A/S$247.05-0.2%$232.68$153.49▼$250.74$15.41B0.41739,020 shs450,896 shsIONSIonis Pharmaceuticals$75.56-0.3%$74.18$32.00▼$86.74$12.49B0.381.93 million shs1.58 million shsRAREUltragenyx Pharmaceutical$23.39-1.3%$23.22$18.29▼$42.37$2.30B0.391.72 million shs1.13 million shsUTHRUnited Therapeutics$568.43+0.5%$563.25$272.12▼$609.35$24.13B0.6415,129 shs281,045 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%-1.40%-4.57%-12.05%-3.43%ASNDAscendis Pharma A/S0.00%+2.72%+9.80%+9.80%+56.26%IONSIonis Pharmaceuticals0.00%+1.79%+1.98%-9.13%+125.55%RAREUltragenyx Pharmaceutical0.00%-6.44%-3.67%+2.95%-33.95%UTHRUnited Therapeutics0.00%-0.03%-0.77%+20.07%+83.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.75Moderate Buy$31.6349.88% UpsideASNDAscendis Pharma A/S 3.00Buy$295.3919.57% UpsideIONSIonis Pharmaceuticals 2.90Moderate Buy$100.9033.54% UpsideRAREUltragenyx Pharmaceutical 2.83Moderate Buy$59.88156.02% UpsideUTHRUnited Therapeutics 2.85Moderate Buy$619.428.97% UpsideCurrent Analyst Ratings BreakdownLatest ACAD, ASND, RARE, IONS, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026RAREUltragenyx Pharmaceutical Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$84.00 ➝ $96.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$355.005/18/2026IONSIonis Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$115.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/18/2026IONSIonis Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/15/2026ASNDAscendis Pharma A/S EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$329.005/11/2026ASNDAscendis Pharma A/S BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$342.00 ➝ $345.005/8/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026ASNDAscendis Pharma A/S Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$330.00 ➝ $326.005/8/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $32.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.37$0.89 per share23.78$7.29 per share2.89ASNDAscendis Pharma A/S$814.57M18.92N/AN/A$9.16 per share26.97IONSIonis Pharmaceuticals$944M13.23N/AN/A$2.97 per share25.44RAREUltragenyx Pharmaceutical$673M3.42N/AN/A($2.40) per share-9.75UTHRUnited Therapeutics$3.18B7.58$32.99 per share17.23$139.02 per share4.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.209.5926.3825.5434.30%9.61%7.07%8/5/2026 (Estimated)ASNDAscendis Pharma A/S-$258M$8.6728.4923.85N/A57.87%N/A-8.37%8/6/2026 (Estimated)IONSIonis Pharmaceuticals-$381.39M-$2.07N/AN/AN/A-30.91%-58.65%-10.07%8/5/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0920.9817.661.8440.62%19.24%17.25%7/29/2026 (Estimated)Latest ACAD, ASND, RARE, IONS, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 million5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million4/29/2026Q1 2026IONSIonis Pharmaceuticals-$0.85-$0.56+$0.29-$0.56$195.57 million$246.00 million2/26/2026Q4 2025ACADACADIA Pharmaceuticals$0.12$1.60+$1.48$1.60$292.54 million$298.00 million2/25/2026Q4 2025IONSIonis Pharmaceuticals-$1.23-$1.41-$0.18-$1.41$156.07 million$203.33 million2/25/2026Q4 2025UTHRUnited Therapeutics$6.78$7.70+$0.92$7.70$814.80 million$790.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48ASNDAscendis Pharma A/S0.791.000.72IONSIonis Pharmaceuticals2.754.104.09RAREUltragenyx PharmaceuticalN/A2.021.85UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ASNDAscendis Pharma A/SN/AIONSIonis Pharmaceuticals93.86%RAREUltragenyx Pharmaceutical97.67%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%ASNDAscendis Pharma A/S40.00%IONSIonis Pharmaceuticals2.60%RAREUltragenyx Pharmaceutical5.20%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableIONSIonis Pharmaceuticals1,402165.26 million160.97 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableACAD, ASND, RARE, IONS, and UTHR HeadlinesRecent News About These CompaniesSwedbank AB Trims Stake in United Therapeutics Corporation $UTHRMay 24 at 7:01 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CFO Sells $5,641,100.00 in StockMay 23 at 7:50 AM | insidertrades.comUnited Therapeutics Corporation $UTHR Holdings Decreased by LSV Asset ManagementMay 23 at 6:39 AM | marketbeat.comMeiji Yasuda Asset Management Co Ltd. Grows Stock Position in United Therapeutics Corporation $UTHRMay 23 at 5:49 AM | marketbeat.comPaul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) StockMay 23 at 4:11 AM | americanbankingnews.comBanque Cantonale Vaudoise Acquires New Stake in United Therapeutics Corporation $UTHRMay 23 at 3:35 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of StockMay 22 at 7:12 PM | marketbeat.comUnited Therapeutics Explores Pig Heart Transplants And Space Labs As Valuation LagsMay 22 at 1:42 PM | finance.yahoo.comInsider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of StockMay 22 at 7:29 AM | insidertrades.comJ.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)May 21 at 7:16 PM | theglobeandmail.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of StockMay 20, 2026 | insidertrades.comQuant ratings on Renaissance Technologies' top holdings: UTHR, PLTR, AAPLMay 20, 2026 | seekingalpha.comUTHR holds as Tyvaso shows 33% lower worsening risk in rare lung scarring diseaseMay 20, 2026 | msn.comUnited Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 SharesMay 19, 2026 | marketbeat.comUnited Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19, 2026 | seekingalpha.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockMay 19, 2026 | americanbankingnews.comUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026May 18, 2026 | businesswire.comHC Wainwright Issues Pessimistic Outlook for UTHR EarningsMay 18, 2026 | americanbankingnews.comHC Wainwright Has Negative Estimate for UTHR Q2 EarningsMay 18, 2026 | marketbeat.comUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026May 17, 2026 | businesswire.comLeuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHRMay 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBefore the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 2026Corning Beats Q1 Estimates but Drops 9% on Guidance MissBy Ryan Hasson | April 29, 2026NVIDIA’s China Connection: Investor Risks With Earnings AheadBy Thomas Hughes | May 5, 2026Why Smart Money Is Quietly Piling Into This Lithium StockBy Jeffrey Neal Johnson | April 29, 2026ACAD, ASND, RARE, IONS, and UTHR Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.10 -0.22 (-1.03%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$21.10 +0.00 (+0.02%) As of 05/22/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Ascendis Pharma A/S NASDAQ:ASND$247.05 -0.46 (-0.19%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$247.18 +0.13 (+0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Ionis Pharmaceuticals NASDAQ:IONS$75.56 -0.22 (-0.29%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$75.43 -0.13 (-0.17%) As of 05/22/2026 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Ultragenyx Pharmaceutical NASDAQ:RARE$23.39 -0.32 (-1.35%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$23.39 0.00 (0.00%) As of 05/22/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.United Therapeutics NASDAQ:UTHR$568.43 +2.56 (+0.45%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$568.09 -0.34 (-0.06%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
